Pfizer (PFE) Stock Forecast & Price Target

Pfizer is a global pharmaceutical company with a diverse product portfolio, including top selling vaccines and prescription drugs, and a strong presence in emerging markets. Its current valuation, with a 9x forward P/E and a 7% dividend yield, reflects potential downside risks such as revenue cliffs and loss of high-margin LOE products, but its strong 1Q26 fundamentals and potential 2026 guidance upgrade provide a solid foundation. Diversity in leadership, particularly in emerging markets, remains an area for improvement but recent executive turnover and restructuring present opportunities for progress. The company's defense of three patents with varying risk profiles, especially the '441 polymorph patent, has potential to add $6 billion in value. In a downside scenario, base business deterioration and margin pressure could lead to a drop in P/E multiple to 7x, resulting in a $20 valuation.

Pfizer is heavily reliant on its top-selling products Prevnar 13, Vyndaqel, and Eliquis, and while it has a diverse portfolio and a strong global presence, its growth is primarily driven by emerging markets. With a high payout ratio limiting M&A flexibility, the timing mismatch between impending LOEs and peak pipeline products does not bode well for its post-2028 earnings outlook, and it remains in the bottom of our investment universe in terms of growth.